9 research outputs found
p38 MAPK and JNK Antagonistically Control Senescence and Cytoplasmic p16INK4A Expression in Doxorubicin-Treated Endothelial Progenitor Cells
Patients treated with low-dose anthracyclines often show late onset cardiotoxicity. Recent studies suggest that this form of cardiotoxicity is the result of a progenitor cell disease. In this study we demonstrate that Cord Blood Endothelial Progenitor Cells (EPCs) exposed to low, sub-apoptotic doses of doxorubicin show a senescence phenotype characterized by increased SA-b-gal activity, decreased TRF2 and chromosomal abnormalities, enlarged cell shape, and disarrangement of F-actin stress fibers accompanied by impaired migratory ability. P16 INK4A localizes in the cytoplasm of doxorubicin-induced senescent EPCs and not in the nucleus as is the case in EPCs rendered senescent by different stimuli. This localization together with the presence of an arrest in G2, and not at the G1 phase boundary, which is what usually occurs in response to the cell cycle regulatory activity of p16INK4A, suggests that doxorubicin-induced p16 INK4A does not regulate the cell cycle, even though its increase is closely associated with senescence. The effects of doxorubicin are the result of the activation of MAPKs p38 and JNK which act antagonistically. JNK attenuates the senescence, p16 INK4A expression and cytoskeleton remodeling that are induced by activated p38. We also found that conditioned medium from doxorubicin-induced senescent cardiomyocytes does not attract untreated EPCs, unlike conditioned medium from apoptotic cardiomyocytes which has a strong chemoattractant capacity. In conclusion, this study provides a better understanding of the senescence of doxorubicin-treated EPCs, which may be helpful in preventing and treating late onset cardiotoxicity
Toll-Like Receptor 9 Is Required for Opioid-Induced Microglia Apoptosis
Opioids have been widely applied in clinics as one of the most potent pain
relievers for centuries, but their abuse has deleterious physiological effects
beyond addiction. However, the underlying mechanism by which microglia in
response to opioids remains largely unknown. Here we show that morphine induces
the expression of Toll-like receptor 9 (TLR9), a key mediator of innate immunity
and inflammation. Interestingly, TLR9 deficiency significantly inhibited
morphine-induced apoptosis in microglia. Similar results were obtained when
endogenous TLR9 expression was suppressed by the TLR9 inhibitor CpGODN.
Inhibition of p38 MAPK by its specific inhibitor SB203580 attenuated
morphine-induced microglia apoptosis in wild type microglia. Morphine caused a
dramatic decrease in Bcl-2 level but increase in Bax level in wild type
microglia, but not in TLR9 deficient microglia. In addition, morphine treatment
failed to induce an increased levels of phosphorylated p38 MAPK and MAP kinase
kinase 3/6 (MKK3/6), the upstream MAPK kinase of p38 MAPK, in either TLR9
deficient or µ-opioid receptor (µOR) deficient primary microglia,
suggesting an involvement of MAPK and µOR in morphine-mediated TLR9
signaling. Moreover, morphine-induced TLR9 expression and microglia apoptosis
appears to require μOR. Collectively, these results reveal that opioids
prime microglia to undergo apoptosis through TLR9 and µOR as well. Taken
together, our data suggest that inhibition of TLR9 and/or blockage of µOR
is capable of preventing opioid-induced brain damage
Cortex Dictamni extracts inhibit over-proliferation and migration of rat airway smooth muscle cells via FAK/p38/Bcl-2 signaling pathway
Glycogen Synthase Kinase-3 and p38 MAPK Are Required for Opioid-Induced Microglia Apoptosis
Opioids have been widely applied in clinics as one of the most potent pain relievers for centuries, but their abuse has deleterious physiological effects beyond addiction. We previously reported that opioids inhibit cell growth and trigger apoptosis in lymphocytes. However, the underlying mechanism by which microglia apoptosis in response to opioids is not yet known. In this study, we show that morphine induces microglia apoptosis and caspase-3 activation in an opioid-receptor dependent manner. Morphine decreased the levels of microglia phosphorylated Akt (p-Akt) and p-GSK-3β (glycogen synthase kinase-3 beta) in an opioid-receptor dependent manner. More interestingly, GSK-3β inhibitor SB216763 significantly increases morphine-induced apoptosis in both BV-2 microglia and mouse primary microglial cells. Moreover, co-treatment of microglia with SB216763 and morphine led to a significant synergistic effect on the level of phospho-p38 mitogen-activated protein kinase (MAPK). In addition, inhibition of p38 MAPK by its specific inhibitor SB203580 significantly inhibited morphine-induced apoptosis and caspase-3 activation. Taken together, our data clearly demonstrates that morphine-induced apoptosis in microglial cells, which is mediated via GSK-3β and p38 MAPK pathways